Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 2014. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding an increase in share interests.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of a specific share transaction rather than a financial performance report.
Material Changes
The filing details a transaction on July 14, 2014, where Mrs. K Thomson (a Connected Person) acquired 55,058 Ordinary Shares. The purchase price was 1,565.78 pence per share. This acquisition resulted from the re-investment of the dividend paid to shareholders on July 10, 2014.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It strictly adheres to the Disclosure and Transparency Rule 3.1.4R(1)(c) regarding the notification of the connected person's transaction.
Investor Verification Points
- Verify the exact number of shares (55,058) acquired by Mrs. K Thomson.
- Confirm the transaction date (July 14, 2014) and the price per share (1,565.78 pence).
- Note that the transaction was a dividend re-investment, not an open market purchase.
- Confirm the notification date to the company was July 18, 2014.